Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shawn Flanagan

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Drugs in R&D|September 30, 2015
Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube AdministrationGerard Kennedy, Jim Osborn, Shawn Flanagan, et al.
Clinical Pharmacology in Drug Development|December 4, 2019
Lack of Effect of Rezafungin on QT/QTc Interval in Healthy SubjectsShawn Flanagan, Daniel B Goodman, Alena Jandourek, et al.
Pharmacotherapy|July 4, 2014
Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolidShawn Flanagan, Edward Fang, Kelly A Muñoz, et al.
Journal of Athletic Training|November 5, 2020
Network Analysis of Sport-related Concussion Research During the Past Decade (2010-2019)Shawn R Eagle, Anthony P Kontos, Michael W Collins, et al.
Pharmacotherapy|June 6, 2024
Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjectsShawn Flanagan, Voon Ong, Thomas Marbury, et al.
Clinical and Translational Science|April 19, 2022
A phase I randomized, double-blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjectsKenan Gu, Dennis Ruff, Cassandra Key, et al.
Expert Opinion on Drug Safety|March 13, 2018
Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infectionsCathy Hardalo, Thomas P Lodise, Monique Bidell, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 2025
Absorption, distribution, metabolism, and excretion of an antiviral drug-Fc conjugate CD388 following subcutaneous administration of <sup>14</sup>C-CD388 in the ratAline Laenen, Shawn Flanagan, Grayson Hough, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 31, 2014
Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphateVoon Ong, Shawn Flanagan, Edward Fang, et al.
Antimicrobial Agents and Chemotherapy|October 31, 2018
Use of Translational Pharmacokinetic/Pharmacodynamic Infection Models To Understand the Impact of Neutropenia on the Efficacy of Tedizolid PhosphateJianying Xiao, Charles Gill, Lianzhu Liang, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Drugs in R&D|September 30, 2015
Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube AdministrationGerard Kennedy, Jim Osborn, Shawn Flanagan, et al.
Clinical Pharmacology in Drug Development|December 4, 2019
Lack of Effect of Rezafungin on QT/QTc Interval in Healthy SubjectsShawn Flanagan, Daniel B Goodman, Alena Jandourek, et al.
Pharmacotherapy|July 4, 2014
Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolidShawn Flanagan, Edward Fang, Kelly A Muñoz, et al.
Journal of Athletic Training|November 5, 2020
Network Analysis of Sport-related Concussion Research During the Past Decade (2010-2019)Shawn R Eagle, Anthony P Kontos, Michael W Collins, et al.
Pharmacotherapy|June 6, 2024
Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjectsShawn Flanagan, Voon Ong, Thomas Marbury, et al.
Clinical and Translational Science|April 19, 2022
A phase I randomized, double-blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjectsKenan Gu, Dennis Ruff, Cassandra Key, et al.
Expert Opinion on Drug Safety|March 13, 2018
Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infectionsCathy Hardalo, Thomas P Lodise, Monique Bidell, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 2025
Absorption, distribution, metabolism, and excretion of an antiviral drug-Fc conjugate CD388 following subcutaneous administration of <sup>14</sup>C-CD388 in the ratAline Laenen, Shawn Flanagan, Grayson Hough, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 31, 2014
Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphateVoon Ong, Shawn Flanagan, Edward Fang, et al.
Antimicrobial Agents and Chemotherapy|October 31, 2018
Use of Translational Pharmacokinetic/Pharmacodynamic Infection Models To Understand the Impact of Neutropenia on the Efficacy of Tedizolid PhosphateJianying Xiao, Charles Gill, Lianzhu Liang, et al.
Pageof 3